CIK 0001870404 · <br>Emerging growth company
CERO THERAPEUTICS HOLDINGS, INC.
Sign in to watch- Tickers
- CERO CEROW
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 871088814
- Phone
- 650-407-2376
- Business address
- 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- CERO THERAPEUTICS HOLDINGS, INC., PHOENIX BIOTECH ACQUISITION CORP.
Securities
- CERO Common stock OTC
- CEROW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-28 | Carter Charles Ross Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-03-25 | Rolfe Lindsey Director | Grant or award · Stock Option (Right to Buy) | +112,500 | 112,500 | ||
| 2024-03-25 | Rapaport Robyn Director | Grant or award · Stock Option (Right to Buy) | +112,500 | 112,500 | ||
| 2024-03-25 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +112,500 | 112,500 | ||
| 2024-03-25 | Ehrlich Christopher B Director | Grant or award · Stock Option (Right to Buy) | +572,182 | 572,182 | ||
| 2024-03-25 | Corey Daniel Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +856,671 | 856,671 | ||
| 2024-03-25 | Carter Charles Ross Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +395,387 | 395,387 | ||
| 2024-03-25 | Byrnes Michael Director | Grant or award · Stock Option (Right to Buy) | +112,500 | 112,500 | ||
| 2024-03-25 | ATWOOD BRIAN G Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +1,317,956 | 1,317,956 | ||
| 2024-02-14 | ATWOOD BRIAN G Chief Executive Officer | Other acquisition | +100,527 | 100,527 | ||
| 2024-02-14 | ATWOOD BRIAN G Chief Executive Officer | Other acquisition | +148,208 | 248,735 | ||
| 2024-02-14 | ATWOOD BRIAN G Chief Executive Officer | Grant or award · Series A Convertible Preferred Stock | +1,002 | $1,000.00 | $1.0M | 1,002 |
| 2024-02-14 | ATWOOD BRIAN G Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +13,857 | 13,857 | ||
| 2024-02-14 | LAPORTE KATHLEEN Director | Grant or award · Series A Convertible Preferred Stock | +50 | $1,000.00 | $50K | 50 |
| 2024-02-14 | ATWOOD BRIAN G Chief Executive Officer | Other acquisition | +100,527 | 100,527 | ||
| 2024-02-14 | ATWOOD BRIAN G Chief Executive Officer | Other acquisition | +148,208 | 248,735 | ||
| 2024-02-14 | ATWOOD BRIAN G Chief Executive Officer | Grant or award · Series A Convertible Preferred Stock | +1,002 | $1,000.00 | $1.0M | 1,002 |
| 2024-02-14 | Loewy Caroline M Director | Other acquisition | +5,828 | 5,828 | ||
| 2024-02-14 | Kosacz Barbara Director | Other acquisition | +5,828 | 5,828 | ||
| 2024-02-14 | Geffken Daniel E. Chief Financial Officer | Other acquisition | +10,002 | 10,002 |
Page 4 of 6 · 120 trades